PL4233847T3 - Tabletka zawierająca pochodną metoksymocznika i cząstki mannitolu - Google Patents

Tabletka zawierająca pochodną metoksymocznika i cząstki mannitolu

Info

Publication number
PL4233847T3
PL4233847T3 PL23172275.2T PL23172275T PL4233847T3 PL 4233847 T3 PL4233847 T3 PL 4233847T3 PL 23172275 T PL23172275 T PL 23172275T PL 4233847 T3 PL4233847 T3 PL 4233847T3
Authority
PL
Poland
Prior art keywords
methoxyurea
tablet
derivative
mannitol particles
mannitol
Prior art date
Application number
PL23172275.2T
Other languages
English (en)
Inventor
Ikuro YAMANE
Yukihiro Nomura
Yutaka Nishimoto
Wataru Hoshina
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56789547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4233847(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of PL4233847T3 publication Critical patent/PL4233847T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL23172275.2T 2015-02-26 2016-02-25 Tabletka zawierająca pochodną metoksymocznika i cząstki mannitolu PL4233847T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015037462 2015-02-26

Publications (1)

Publication Number Publication Date
PL4233847T3 true PL4233847T3 (pl) 2024-11-18

Family

ID=56789547

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16755593.7T PL3263110T3 (pl) 2015-02-26 2016-02-25 Tabletka zawierająca pochodną metoksymocznika i cząstki mannitolu
PL23172275.2T PL4233847T3 (pl) 2015-02-26 2016-02-25 Tabletka zawierająca pochodną metoksymocznika i cząstki mannitolu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL16755593.7T PL3263110T3 (pl) 2015-02-26 2016-02-25 Tabletka zawierająca pochodną metoksymocznika i cząstki mannitolu

Country Status (24)

Country Link
US (2) US10350170B2 (pl)
EP (3) EP4233847B1 (pl)
JP (1) JP6730978B2 (pl)
CN (1) CN107249590A (pl)
AU (1) AU2016224503B2 (pl)
BR (1) BR112017018173A2 (pl)
CA (1) CA2978223A1 (pl)
CY (1) CY1126118T1 (pl)
DK (2) DK3263110T3 (pl)
ES (2) ES2950995T3 (pl)
FI (2) FI4233847T3 (pl)
HR (1) HRP20230613T1 (pl)
HU (1) HUE062269T2 (pl)
IL (1) IL254132B (pl)
LT (1) LT3263110T (pl)
MX (1) MX373225B (pl)
MY (1) MY180680A (pl)
PL (2) PL3263110T3 (pl)
PT (1) PT3263110T (pl)
RS (1) RS64377B1 (pl)
SI (2) SI4233847T1 (pl)
SM (1) SMT202300221T1 (pl)
TW (1) TWI744224B (pl)
WO (1) WO2016136849A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202200255T1 (it) 2012-09-28 2022-07-21 Takeda Pharmaceuticals Co Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea
WO2018060501A2 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methods of treating uterine fibroids and endometriosis
SI3518932T1 (sl) 2016-09-30 2025-03-31 Takeda Pharmaceutical Company Limited Zdravljenje raka prostate
SG11202001436YA (en) 2017-08-18 2020-03-30 Abbvie Inc Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
TW201912157A (zh) 2017-08-18 2019-04-01 美商艾伯維有限公司 治療子宮內膜異位症、子宮纖維瘤、多囊性卵巢症候群及子宮腺肌症之固體醫藥調配物
WO2019178304A1 (en) 2018-03-14 2019-09-19 Teva Pharmaceuticals International Gmbh Solid state forms of relugolix
CA3145993A1 (en) 2019-08-02 2021-02-11 Johnson Matthey Public Limited Company Solid-state forms of relugolix
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー N-(4-(1-(2,6-ジフルオロベンジル)-5-((ジメチルアミノ)メチル)-3-(6-メトキシ-3-ピリダジニル)-2,4-ジオキソ-1,2,3,4-テトラヒドロチエノ[2,3-d]ピリミジン-6-イル)フェニル)-N’-メトキシ尿素の結晶形
WO2021069700A1 (en) 2019-10-10 2021-04-15 Myovant Sciences Gmbh Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
EP4151219A4 (en) 2020-05-15 2024-05-15 Shionogi & Co., Ltd DRUG COMPOSITION WITH INHIBITED IMPURITIES PRODUCTION
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
WO2022101303A1 (en) 2020-11-11 2022-05-19 Myovant Sciences Gmbh Methods of administering relugolix
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN115671069A (zh) * 2022-11-24 2023-02-03 北京鑫开元医药科技有限公司 一种瑞卢戈利片剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW284688B (pl) 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
FR2710637B1 (fr) * 1993-09-28 1995-12-08 Roquette Freres Mannitol pulvérulent de friabilité modérée et son procédé de préparation.
TW449600B (en) 1994-04-19 2001-08-11 Takeda Chemical Industries Ltd Condensed-ring thiophene derivatives, their production and use
JP3854648B2 (ja) * 1994-04-19 2006-12-06 武田薬品工業株式会社 縮合チオフェン誘導体、その製造法及び用途
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
JP5072166B2 (ja) * 2002-01-30 2012-11-14 武田薬品工業株式会社 チエノピリミジン化合物、その製造法および用途
EP1479684A4 (en) 2002-01-30 2006-01-04 Takeda Pharmaceutical THIENOPYRIMIDINES, METHODS OF MAKING AND USING SAME
CN1326569C (zh) * 2002-02-26 2007-07-18 阿斯特拉曾尼卡有限公司 含有水溶性纤维素衍生物的iressa药物制剂
CN101153042A (zh) 2003-01-29 2008-04-02 武田药品工业株式会社 噻吩并嘧啶化合物及其用途
JP4039574B2 (ja) * 2003-01-29 2008-01-30 武田薬品工業株式会社 チエノピリミジン化合物およびその用途
JP2006035365A (ja) * 2004-07-26 2006-02-09 Hitachi Koki Co Ltd 携帯用切断工具
US20110172249A1 (en) * 2008-09-03 2011-07-14 Takeda Pharmaceutical Company Limted Method for improving absorbability of preparation, and preparation having improved absorbability
JP2015037462A (ja) 2012-06-01 2015-02-26 株式会社コナミデジタルエンタテインメント ゲーム装置、ゲーム方法、及びプログラム
SMT202200255T1 (it) 2012-09-28 2022-07-21 Takeda Pharmaceuticals Co Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea
EP2945628B1 (en) 2013-01-15 2020-04-15 Aragon Pharmaceuticals, Inc. Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer

Also Published As

Publication number Publication date
DK3263110T3 (da) 2023-07-31
AU2016224503A1 (en) 2017-09-14
US10350170B2 (en) 2019-07-16
EP4233847B1 (en) 2024-07-10
PT3263110T (pt) 2023-08-01
JP6730978B2 (ja) 2020-07-29
RS64377B1 (sr) 2023-08-31
SI3263110T1 (sl) 2023-09-29
MY180680A (en) 2020-12-06
HUE062269T2 (hu) 2023-10-28
BR112017018173A2 (pt) 2018-04-10
IL254132B (en) 2020-02-27
EP3263110B1 (en) 2023-05-10
TWI744224B (zh) 2021-11-01
HRP20230613T1 (hr) 2023-09-29
PL3263110T3 (pl) 2023-11-06
EP3263110A4 (en) 2018-11-07
ES2988678T3 (es) 2024-11-21
WO2016136849A1 (ja) 2016-09-01
FI3263110T3 (fi) 2023-07-25
JPWO2016136849A1 (ja) 2017-12-07
LT3263110T (lt) 2023-07-10
TW201639575A (zh) 2016-11-16
MX2017010945A (es) 2018-07-06
EP4454708A3 (en) 2024-11-13
FI4233847T3 (fi) 2024-09-24
EP3263110A1 (en) 2018-01-03
IL254132A0 (en) 2017-10-31
AU2016224503B2 (en) 2021-07-08
US20200000730A1 (en) 2020-01-02
EP4454708A2 (en) 2024-10-30
SMT202300221T1 (it) 2023-09-06
SI4233847T1 (sl) 2025-02-28
DK4233847T3 (da) 2024-09-30
CN107249590A (zh) 2017-10-13
ES2950995T3 (es) 2023-10-17
MX373225B (es) 2020-04-08
CY1126118T1 (el) 2023-11-15
CA2978223A1 (en) 2016-09-01
NZ735026A (en) 2021-09-24
US20180036250A1 (en) 2018-02-08
EP4233847A1 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
SI4233847T1 (sl) Tableta, ki vsebuje derivat metoksiuree in delce manitola
IL249186A0 (en) Anti-cd20 glycoantibodies and their uses
IL252532A0 (en) Polycyclic carbamoylpyridone compounds and their pharmaceutical use
AU356804S (en) Tablet
IL254818B1 (en) Ribociclib tablet
SG10201914087UA (en) Tablet
IL253457B (en) Polymyxin derivatives, preparations containing them and their uses
PL3328361T3 (pl) Cząstki nanożywicy zawierające lek
IL247978A0 (en) Modified sulfamidase and its production
PL3156713T3 (pl) Podstawa telewizora i telewizor o płaskim ekranie
GB201420300D0 (en) Tablet
TWI563001B (en) Disintegrin variants and pharmaceutical uses thereof
IL250160A0 (en) medicinal substance
AU356801S (en) Tablet
GB201511252D0 (en) Tablet
ZA201708393B (en) Large particles
TWM532873U (en) Tablet structure
GB201419354D0 (en) Pharmaceutical extracts and uses thereof
PH32014000079S1 (en) Pharmaceutical tablet
GB201505546D0 (en) Incinerators and chimleys
AU356805S (en) Tablet
GB201411471D0 (en) Tablet